AEON Biopharma Inc. (NYSE American: AEON) announced it received a notice from the NYSE American exchange on March 31, 2026, indicating non-compliance with continued listing standards.
The notice was issued following the company's year-end financial results, according to a statement from AEON Biopharma. This is an additional notice for the biopharmaceutical company, which is working to bring its Botox biosimilar, ABP-450, to the U.S. market.
The specific standard not being met was not detailed in the initial announcement. NYSE American listing standards cover various financial and governance metrics, including shareholder equity, market capitalization, and stock price.
A notice of non-compliance is a serious warning that can precede a formal delisting process if the company cannot regain compliance within a specified timeframe. Such a development often raises concerns among investors, as a delisting would severely impact the stock's liquidity and marketability.
The notice requires AEON to submit a plan of compliance to the exchange outlining how it intends to resolve the deficiency. For investors, this introduces a significant risk, and the company's next announcements regarding its compliance plan will be a critical catalyst.
This article is for informational purposes only and does not constitute investment advice.
